Use of florbetapir-PET for imaging beta-amyloid pathology.
Evidence is provided that a molecular imaging procedure can identify β-amyloid pathology in the brains of individuals during life and for the prediction of progression to dementia.
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects
Florbetapir F 18 appears to have a wide effective dose range and a high test–retest reliability for both quantitative (SUVr) values and visual assessment of the ligand, and these imaging performance properties provide important technical information on the use of florbetapIR F 18 and PET to detect cerebral amyloid aggregates.
A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patch versus capsule
- B. Winblad, J. Cummings, R. Lane
- Medicine, PsychologyInternational Journal of Geriatric Psychiatry
- 1 May 2007
To compare the efficacy, safety and tolerability of a novel rivastigmine transdermal patch with conventional rivastigmine capsules and placebo in patients with Alzheimer's disease (AD).
Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis
Imaging results suggest that intra-brain vascular dysregulation is an early pathological event during disease development, suggesting early memory deficit associated with the primary disease factors.
A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease
Tacrine produced statistically significant, dose-related improvements on objective performance-based tests, clinician- and caregiver-rated global evaluations, and measures of quality of life.
Practical Guidelines for the Recognition and Diagnosis of Dementia
Practical guidance for the recognition and diagnosis of dementia is provided, with clearly defined steps for screening and diagnosing AD and assessing daily functioning, behavioral symptoms, and caregiver status.
Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline
Florbetapir PET may help identify individuals at increased risk for progressive cognitive decline and convert to AD dementia at a higher rate than Aβ− subjects.
Guidelines for the Management of Cognitive and Behavioral Problems in Dementia
- C. Sadowsky, J. Galvin
- Medicine, PsychologyJournal of the American Board of Family Medicine
- 1 May 2012
The effects of nonpharmacologic and pharmacologic interventions on the functional abilities and behavior of patients with dementia and how these can be implemented into clinical practice are reviewed.